The Effects of Thyrotropin-Suppressive Therapy on Bone Metabolism in Patients with Well-Differentiated Thyroid Carcinoma
- 1 June 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 16 (6) , 583-591
- https://doi.org/10.1089/thy.2006.16.583
Abstract
Patients with differentiated thyroid carcinoma (DTC) are commonly treated long-term with thyrotropin (TSH)- suppressive thyroxine replacement therapy resolving in a state of subclinical hyperthyroidism. The relationship between subclinical hyperthyroidism and osteoporosis is not clear. In this review, we systematically selected and analyzed 21 studies addressing this issue. Although multiple methodological differences between studies prevented a structured meta-analysis, our data suggest that postmenopausal women with subclinical hyperthyroidism are most at risk, whereas no increased risk was observed in men and premenopausal women. Based on these findings we believe that measurement of bone mineral density is recommended in postmenopausal women with DTC starting TSH suppressive therapy. This should be subsequently regularly measured to enable timely intervention with bone protective agents.Keywords
This publication has 69 references indexed in Scilit:
- A Novel Interaction between Thyroid Hormones and 1,25(OH)2D3 in Osteoclast FormationBiochemical and Biophysical Research Communications, 2002
- Suppressive Levothyroxine Therapy has no Significant Influence on Bone Degradation in Women with Thyroid Carcinoma: A Comparison with Other Disorders Affecting Bone MetabolismThyroid®, 2001
- Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell CulturesBiochemical and Biophysical Research Communications, 1998
- Possible Limited Bone Loss with Suppressive Thyroxine Therapy Is Unlikely to Have Clinical RelevanceThyroid®, 1995
- Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal womenJournal of Clinical Endocrinology & Metabolism, 1994
- Thyroxine suppressive therapy decreases bone mineral density in post‐menopausal womenClinical Endocrinology, 1993
- Long-term thyroxine treatment and bone mineral densityThe Lancet, 1992
- Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post‐menopausal womenClinical Endocrinology, 1992
- Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitroBiochemical and Biophysical Research Communications, 1991
- Trabecular bone remodeling and bone balance in hyperthyroidismBone, 1985